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Figure S1
Figure S1: Characterisation of previously unpublished iPSC clones 2B, 2C and 3C, related to
Experimental Procedures and Figure 1.
(A) Retroviral transgene silencing in iPSC lines 2B and 2C by qRT-PCR for each transgene, normalised to actin
endogenous control, relative to expression of transgenes from fibroblasts 5 days post-infection with the
Yamanaka reprogramming retroviruses (HDF+Y), with uninfected fibroblasts (HDF) as a negative control.
(B) CytoTune Sendai virus clearance shows the correct size band for β-actin, and no bands corresponding to the 
reprogramming virus RT-PCR product sizes for iPSC line 3C; L, Log2 ladder; Se, Sendai backbone 181 bp; S,
Sox2 451 bp; K, Klf4 410 bp; M, c-myc 532 bp; O, Oct-4 483 bp; A, β-actin control 92 bp; + control, fibroblasts 
infected with CytoTune 5 days previously.
(C) PluriTest analysis of Illumina HT12v4 transcriptome array data shows the tested iPSC lines cluster in the
red cloud representing pluripotent cell lines and not with differentiated cells (blue clouds).
(D) iPSC lines express expected pluripotency proteins as shown by FACs for Tra-1-60 and Nanog (grown
feeder-free); open black plot represents antibody, filled grey plot is isotype control; Right-hand panel shows the
expected iPSC colony morphology, with high nucleus to cytoplasm ratio by phase-contrast microscopy; 2B is
photographed on matrigel, 2C on feeders, 3C photographed one day after thawing onto matrigel, so not yet
clustered tightly together. Scale bar = 100 µm.
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Figure S2
Figure S2: Further characterisation of previously unpublished iPSC clones 2B, 2C and 3C, related to
Experimental Procedures and Figure 1.
Genome integrity was assessed by Illumina Human CytoSNP-12v2.1 or OmniExpress24 SNP array and
karyograms produced using KaryoStudio software (Illumina); autosome amplifications (green), deletions
(orange) and LOH regions (grey) are shown alongside the relevant chromosome; single-copy sex chromosomes
are annotated orange, X chromosomes for females are grey.
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Figure S3
Figure S3: Schematics of the human MAPT locus and quantitative RT-PCR assays, related to Figures 2
and 4.
(A) The human MAPT locus on chromosome 17q21.31 contains 16 exons; exons 2, 3 and 10 (coloured) are
subject to alternative splicing, exons 9-12 encode microtubule-binding domains with a high degree of sequence
similarity and exons 4A, 6 and 8 (white) are not expressed in the adult central nervous system.
(B) Adult human brain expresses six major isoforms of tau protein through the alternative splicing of exons 2, 3
and 10. The locations of the standard (not allele-specific) TaqMan-based quantitative RT-PCR expression
assays used in this study are shown in green.
(C-E) Schematics of the allele-specific TaqMan-based expression assays exploiting haplotype-tagging SNPs to
distinguish the allelic origin of transcripts, with the H1 or H2 allele shown respectively as a green or red
diamond. TaqMan probes bearing FAM (green) or VIC (red) are shown as coloured lines below the SNP.
Arrows denote primers to amplify from genomic DNA (orange) or cDNA (purple). (C) Allele-specific assay for
total MAPT transcripts using SNP rs17650901 (SNP1) in exon 1. (D) Allele-specific assay for exon 3+ MAPT
transcripts also using SNP rs17650901 (SNP1) in exon 1. (E) Allele-specific assay for exon 10+ MAPT
transcripts using SNP rs17652121 in exon 9 (SNP9ii).
(F-G) Standard curves for (F) the allele-specific expression assay using SNP1 (rs17650901) and (G) the allele-
specific expression assay using SNP9ii (rs17652121). Standard curves were generated using MAPT H1 PAC
and MAPT H2 PAC in ratios from 8:1 to 1:8. The values of ∆CT (H1-H2) were plotted against the log(2) H1:H2
ratio, then corrected to remove the value of the y-intercept (to bring the graph through the origin).
-4 -2 2 4
-4
-2
2
4
Y = -0.9558*X -
Log(2) H1:H2 Ratio
Corrected DCT (H1-H2)
-4 -2 2 4
-4
-2
2
4
Y = -0.8358*X +
Log(2) H1:H2 Ratio
Corrected DCT (H1-H2)
C E
rs17650901
EX 1EX 0
EX 1EX 0
EX 2
EX 2
EX 3
EX 3
H1
H2
A
G EX 9 EX 10
EX 9 EX 10
rs17652121
H1
H2
T
C
F G
A
B
STH
0 1 2 3 4 4A 5 6 7 8 9 10 11 12 13 14
MAPT
1 2 3 42N4R 441
1 2 3 41N4R 412
12N3R 3 4 410
11N3R 3 4 381
1 2 3 40N4R 383
N-terminal
segments
Microtubule binding
repeats
10N3R 3 4 352
Proline-rich region
aaIsoform
Ex3+ Ex10+ Total
D
rs17650901
EX 1EX 0
EX 1EX 0
A
G
H1
H2
Total MAPT allele-specificassay Exon 3+ MAPT allele-specificassay Exon 10+ MAPT allele-specificassay
Figure S4
Figure S4: Allele-specific MAPT expression assays on dopaminergic neuronal cultures over 24-week
maturation, related to Figure 4.
(A-C) Data from allele-specific TaqMan-based quantitative RT-PCR expression assays on samples from three
points of a time course of maturation of dopaminergic neuronal cultures: DIV48, DIV124 and DIV188. Each
graph shows mean ±SEM, n=7 clones (all clones except clone 1A). Asterisks denote significant statistical
difference from hypothetical mean of 1 in a one-sample t-test: (A) DIV48, mean=1.020 ± 0.031, n.s.; DIV124,
mean=1.109 ± 0.031, p=0.0132, t=3.478, df=6; DIV188, mean=1.305 ± 0.024, p<0.0001, t=12.58, df=6;
(B) DIV48, mean=0.832 ± 0.183, n.s.; DIV124, mean=0.588 ± 0.038, p<0.0001, t=10.97, df=6; DIV188,
mean=0.524 ± 0.034, p<0.0001, t=13.95, df=6; (C) DIV48, mean=0.635 ± 0.069, p=0.0019, t=5.280, df=6;
DIV124, mean=0.776 ± 0.103, n.s.; DIV188, mean=0.689 ± 0.070, p=0.0044, t=4.437, df=6.
(D) Subdivision of graph C to separate out individual 3, which consistently showed a distinct phenotype relative
to exon 10. Individuals 1-2, n=4 clones; individual 3, n=3 clones. Asterisks denote significant statistical
difference from hypothetical mean of 1 in a one-sample t-test: individuals 1-2 DIV48, mean=0.780 ± 0.013,
p=0.0005, t=16.50, df=3; individuals 1-2 DIV124, mean=0.991 ± 0.030, n.s.; individuals 1-2 DIV188,
mean=0.837 ± 0.014, p=0.0013, t=11.74, df=3; individual 3 DIV48, mean=0.441 ± 0.019, p=0.0011, t=29.85,
df=2; individual 3 DIV124, mean=0.488 ± 0.006, p=0.0002, t=81.41, df=2; individual 3 DIV188, mean=0.492 ±
0.006, p=0.0002, t=81.39, df=2.
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Figure S5: Splice factor binding site and expression analysis, related to Figure 5. Screen shots of splice
factor binding analysis with Splice Aid 2 online tool (http://193.206.120.249/splicing_tissue.html, version
February 2013, 71 splicing factors, 2339 RNA binding sites, accessed February 2016) (Piva et al. 2012) using
an input of (A) a 57 bp portion of the consensus sequence of MAPT intron 10 and (B) the equivalent 54 bp
∆CTT sequence as in control 3. Splice factors that promote exon inclusion or exclusion are shown as blocks 
respectively above or below the central line. Unlike the consensus sequence, the ∆CTT variant sequence is not 
predicted to be bound by RBM4 (blue box above) or hnRNP I (PTB; light green box below). All known splicing
factors were included in this search, rather than restricting by tissue type.
(C-F) Quantitative RT-PCR expression over the time course of maturation for dopaminergic neuronal cultures
from DIV27 to DIV188. (C-D) qRT-PCR expression data for RBM4 and PTBP1 (PTB/hnRNP I). Both splice
factors are significantly expressed at the RNA level from at least DIV48 onwards but show no correlation with
the rising inclusion of exon 10 (see part D). No significant difference is observed for control 3. Bars represent
mean of three technical values of n=1 cDNA sample, with each of the three individuals (one clone per
individual) represented as a separate bar.
(E) Alternative representation of the data from graphs A-B to reveal correlation of the expression of RBM4 and
PTBP1 transcripts across the time course; statistical results for Pearson correlation are presented on the graph.
(F) qRT-PCR expression data for MAPT exon 10+ transcripts, representing a subdivision of Fig. 2C to separate
out individual 3 bearing the ∆CTT variant. Individuals 1-2, n=4 clones; individual 3, n=3 clones.  Asterisk 
denotes significant statistical difference between groups in a multiple one-sample t-test with Sidak-Bonferroni
multiple comparison correction: mean1-2=14.91 ± 1.85, mean3=22.66 ± 1.98, p=0.000133, t=4.36, df=31
Figure S6
Figure S6. Stratified mitochondrial axonal transport data for iPSC-derived dopaminergic neuronal
cultures, related to Figure 6. Legend for all parts at bottom of figure. Cumulative frequency (%) graphs of
average mitochondrial velocity in dopaminergic neuronal cultures after stratification by directionality.
(A-D) Stratified axonal transport data for cultures around four weeks post-transduction. (A) Total velocity
measurements for unidirectional mitochondria; (B) velocity without pause periods for unidirectional
mitochondria; (C) Total velocity measurements for bidirectional mitochondria; (D) velocity without pause
periods for bidirectional mitochondria. Median velocities (IQR): (A) total MAPT shRNA, 0.882 (1.187) μm/s; 
non-targeting shRNA, 0.658 (0.908) μm/s; untransduced, 0.530 (1.139) μm/s; (B) total MAPT shRNA, 0.992 
(1.011) μm/s; non-targeting shRNA, 0.869 (0.965) μm/s; untransduced, 0.671 (1.134) μm/s; (C) total MAPT 
shRNA, 0.096 (0.182) μm/s; non-targeting shRNA, 0.121 (0.130) μm/s; untransduced, 0.080 (0.092) μm/s; (D) 
total MAPT shRNA, 0.173 (0.256) μm/s; non-targeting shRNA, 0.195 (0.202) μm/s; untransduced, 0.146 
(0.141) μm/s. Kruskall-Wallis test found a significant statistical difference between medians for (A) (p=0.0097, 
KW statistic=9.264) but Dunn’s multiple comparisons post test showed no statistical difference from non-
targeting shRNA control (total MAPT shRNA, adjusted p=0.2327). Kruskall-Wallis tests for (B-D) found no
significant difference between medians: (B) p=0.0502, KW statistic=5.984; (C) p=0.1458, KW statistic=3.851;
(D) p=0.1786, KW statistic=3.445. Number of mitochondria per condition (unidirectional/bidirectional): total
MAPT shRNA, 133/102; non-targeting shRNA, 102/93; untransduced, 112/100.
(E-H) Stratified axonal transport data for cultures around five months post-transduction. (E) Total velocity
measurements for unidirectional mitochondria; (F) velocity without pause periods for unidirectional
mitochondria; (G) Total velocity measurements for bidirectional mitochondria; (H) velocity without pause
periods for bidirectional mitochondria. Median velocities (IQR): (E) 4R MAPT shRNA, 0.760 (0.752) μm/s; 
total MAPT shRNA, 0.723 (1.202) μm/s; non-targeting 0.344 (0.573) μm/s; untransduced, 0.458 (0.718) μm/s; 
(F) 4R MAPT 0.990 (0.626) μm/s; total MAPT shRNA, 0.946 (1.056) μm/s; non-targeting 0.641 (0.827) μm/s; 
untransduced, 0.913 (0.660) μm/s; (G) 4R MAPT 0.085 (0.131) μm/s; total MAPT shRNA, 0.120 (0.193) μm/s; 
non-targeting 0.093 (0.113) μm/s; untransduced, 0.076 (0.106) μm/s; (H) 4R MAPT 0.214 (0.215) μm/s; total 
MAPT shRNA, 0.294 (0.389) μm/s; non-targeting 0.184 (0.154) μm/s; untransduced, 0.153 (0.145) μm/s. 
Kruskall-Wallis tests found significant statistical differences between medians for all graphs: (E) p=0.0075, KW
statistic=11.97; (F) p=0.0030, KW statistic=13.96; (G) p=0.0113, KW statistic=11.09; (H) p=0.0022, KW
statistic=14.59. Asterisks represent significant statistical difference from non-targeting shRNA control in
Dunn’s multiple comparisons tests: (E) 4R MAPT shRNA, p=0.0048; (F) 4R MAPT shRNA, p=0.0033; total
MAPT shRNA, p=0.0078; (G) no significance in post test; (H) total MAPT shRNA, p=0.0327. Number of
mitochondria per condition (unidirectional/bidirectional): 4R MAPT shRNA, 70/29; total MAPT, 52/46; non-
targeting shRNA, 39/29; untransduced, 49/66.
.
Table S1: iPSC clones used in this study, Related to Figure 1.
OPDC
(StemBANCC)
codes
Age at
biopsy
Sex MAPT
genotype
Clones used Paper
ID
Reprogramming
Method
Previous
Characterisation
NHDF 44 F H1/H2 NHDF-1
NHDF-2
1A
1B
Retrovirus
Retrovirus
Hartfield et al. (2014)
Hartfield et al. (2014)
AH016 80 M H1/H2 AH016-3
AH016-6
AH016-10
2A
2B
2C
Retrovirus
Retrovirus
Retrovirus
Sandor et al. (2017)
-
-
OX1 (SFC841) 36 M H1/H2 OX1-19
SFC841-03-01
SFC841-03-02
3A
3B
3C
Retrovirus
CytoTune
CytoTune
van Wilgenburg et al.
(2013)
(Dafinca et al., 2016)
-
Supplemental Experimental Procedures
Genotyping, sequencing and sub-cloning
Genomic DNA was extracted from cultured cells using the Illustra tissue and cells genomicPrep Mini Spin Kit
(GE Healthcare, Amersham, UK). MAPT H1/H2 genotyping reactions were performed using AmpliTaq Gold
DNA Polymerase with Gold Buffer and 2.5 mM MgCl2 (Applied Biosystems), with primers to amplify around
the 238 bp indel in MAPT intron 9 (Table S2). To determine the sequence around MAPT exons 9 and 10, initial
amplification PCRs from genomic DNA using AmpliTaq Gold were cleaned up using FastAP
(ThermoScientific) and Exonuclease I (New England BioLabs (NEB)) before a second single-primer reaction
with BigDye Terminator v3.1 kit (Applied Biosystems) and sequencing on a 3730xl DNA Analyzer (Applied
Biosystems) at the Zoology Sequencing Facility, University of Oxford.
Products from allele-specific amplification of the region around MAPT exon 10 by AmpliTaq Gold were ligated
into pGEM-T Easy (Promega) and electroporated into NEB 10-beta electrocompetent E. coli (NEB) prior to
blue-white selection on ampicillin-agar. Plasmids were isolated using the QIAprep Spin Miniprep kit
(QIAGEN) and sequenced directly with BigDye.
Induced pluripotent stem cells
iPSC lines used in this manuscript are detailed in Table S1. The existing lines NHDF-1 and NHDF-2 (Hartfield
et al., 2014) were used as clones 1A and 1B in this study. Further lines were generated from two MAPT H1/H2
healthy control individuals screened within the Oxford Parkinson’s Disease Cohort following reprogramming
either by retroviral delivery as previously described (clones 2A, 2B, 2C, 3A)(Hartfield et al., 2014; van
Wilgenburg et al., 2014) or using the CytoTune-iPS Sendai Reprogramming kit (Invitrogen) (Fernandes et al.,
2016) (clones 3B, 3C). Clones were adapted to feeder-free culture conditions in mTeSR™1 (StemCell
Technologies), on hESC-qualified Matrigel-coated plates (BD), and routinely passaging as clumps using 0.5
mM EDTA in PBS (Beers et al., 2012). Large-scale SNP-QCed batches were frozen at p15-25 and used for
experiments within a minimal number of passages post-thaw to ensure consistency.
QC analyses for previously unpublished clones are shown in Figure S1-S2, and were carried out as described
previously (Hartfield et al., 2014) (Fernandes et al., 2016). FACs for pluripotency markers TRA-1-60 and
Nanog (B119983, IgM-488, Biolegend; 2985S, IgG-647, Cell Signaling, with appropriate isotype controls,
using the same concentration and supplier), was measured using a FACS Calibur (Becton Dickinson), and
analysis using FlowJo.
Silencing of retrovirally-delivered reprogramming genes was assessed by quantitative RT-PCR as previously
described (Hartfield et al., 2014). Clearance of Cytotune Sendai virus-delivered reprogramming genes was
performed as previously described (Fernandes et al., 2016) by RT-PCR, run on a 1.5% agarose gel with Log2
ladder (NEB). Positive controls (fibroblasts infected 5 days previously) were always run in parallel. Primers
were SeV F: GGATCACTAGGTGATATCGAGC, R: ACCAGACAAGAGTTTAAGAGATATGTATC 181bp;
SOX2 F: ATGCACCGCTACGACGTGAGCGC, R: AATGTATCGAAGGTGCTCAA 451bp; KLF4 F:
TTCCTGCATGCCAGAGGAGCCC, R: AATGTATCGAAGGTGCTCAA 410bp; c-MYC F:
TAACTGACTAGCAGGCTTGTCG, R: TCCACATACAGTCCTGGATGATGATG 532bp; OCT4 F:
CCCGAAAGAGAAAGCGAACCAG, R: AATGTATCGAAGGTGCTCAA 483bp; β-Actin control 
Eurogentec 92 bp.
Assessment of conformity to pluripotent gene expression profile was performed using Illumina’s Human-HT-
12-v4 expression BeadChip and Pluritest (Muller et al., 2011) (pluritest.org).
Genome integrity and cell-line tracking was assessed by Illumina Human CytoSNP-12v2.1 beadchip array
(~300,000 markers) or OmniExpress24 array (700,000 markers), with genomic DNA made using an All-Prep kit
(Qiagen) and analysis used GenomeStudio and Karyostudio software (Illumina). The accession number for the
Illumina SNP genotype and HT12v4 expression array datasets reported in this paper is GEO: GSE99125.
Differentiation of induced pluripotent stem cells to dopaminergic neuronal cultures
All cell cultures were maintained at 37ºC, 5% CO2. Induced pluripotent stem (iPS) cells were maintained in 6-
well plates coated with hESC-qualified Matrigel (Corning) with mTeSR1 medium (StemCell Technologies)
changed daily. ROCK inhibitor (10 µM Y-27632) (Tocris Bioscience) was used for 24 hours after single cell
passaging performed with TrypLE Express incubation (Life Technologies). iPS cells were differentiated into
dopaminergic neuronal cultures according to a modified protocol of Kriks et al (Kriks et al., 2011). Prior to
commencing differentiation, iPS cells were passaged as single cells and seeded in 6-well plates coated with
Geltrex (Life Technologies) then grown to confluency. Basal media are as follows (Life Technologies unless
stated): KO DMEM KSR = Knockout DMEM, Knockout serum replacement, 1X non-essential amino acids, 2
mM L-glutamine, 10 µM 2-mercaptoethanol (Sigma); NNB = Neurobasal medium, 0.5X N2 supplement, 0.5X
B27 supplement, 2mM L-glutamine; NB = Neurobasal medium, 1X B27 supplement, 2mM L-glutamine.
Differentiation factors added to basal media are as follows: 100 nM LDN-193189 (Sigma), 10 µM SB-431542
(Tocris Bioscience), 100 ng/ml recombinant sonic hedgehog C24II (R&D Systems), 2 µM purmorphamine
(Calbiochem), 100 ng/ml fibroblast growth factor 8a (R&D Systems), 3 µM CHIR-99021 (Tocris Bioscience),
20 ng/ml brain-derived neurotrophic factor (Peprotech), 20 ng/ml glial cell line-derived neurotrophic factor
(Peprotech), 1 ng/ml transforming growth factor β3 (Peprotech), 10 µM DAPT (abcam), 200 µM ascorbic acid 
(Sigma), 500 µM dibutyryl cAMP (Sigma). Medium containing differentiation and neurotrophic factors was
fully changed every two days with half change every other day until day 20 of the protocol when cells were
dissociated with StemPro Accutase (Life Technologies) and re-plated onto poly-L-ornithine with laminin and
fibronectin or Geltrex in the desired format and density per experiment, ranging from spots of 5x104 cells to an
even monolayer of 3x105 cells/cm2. Cultures were treated with 1 µg/ml mitomycin C in NB medium for 1 hour
to remove proliferating cells and washed with neurobasal medium before returning to fresh maturation medium.
After a full medium change three days later to remove dead cells, medium was half changed every 2-3 days for
the remaining period of maturation up to DIV190. For biochemical analysis of protein or RNA, cultures were
washed in PBS, detached by scraping in fresh PBS, micro-centrifuged (1200 x g, 5 min, 4ºC), snap frozen on
dry ice and stored at -80ºC until ready for lysis.
Primers used for PCR, sequencing and cloning
Primer Name Primer Sequence (5’-3’) Primer Purpose
tau_indel_F GGAAGACGTTCTCACTGATCTG Genotyping H1/H2 (238 bp indel)
tau_indel_R AAGAGTCTGGCTTCAGTCTCTC
M13_F GTAAAACGACGGCCAGT Sequencing of sub-clones in pGEM-T Easy
M13_R CAGGAAACAGCTATGAC
MAPT_Int9seqF TGTGAAGTGAGGACCTGCAA Sequencing upstream of MAPT exon 10
MAPT_Int9seqR AAAAGGATGAGTGACACGCC
MAPTEx10seqF CTCTGCCAAGTCCGAAAGTG Sequencing MAPT exon 10 and environs
MAPTEx10seqR GGTCCGTCATCTGCCCTATT
MAPT_int9_H1F GAAATGCAGTCGTGGGAGAC Generation of H1 sub-clone (with MAPTEx10seqR)
MAPT_int9_H2F TGGTTTTCTATTTCACAGCCCC Generation of H2 sub-clone (with MAPTEx10seqR)
RBM4_F GCCGCCATTTTAGCGTTTTG SyBr Green qPCR of RBM4
RBM4_R CACATTCCAGCACCTTCCCA
PTBP1_F TTGGGTCGGTTCCTGCTATT SyBr Green qPCR of PTBP1
PTBP1_R CGTCAGATCCCCGCTTTGT
Allele-specific qRT-PCR
Specificity for the reactions was achieved with 5X SNP1 probe concentration, 3X SNP9ii probe concentration
and 900 nM primers. H1:H2 ratios were calculated as follows: 2^(-1.194*[(cDNA ∆CT H1-H2) – (Mean
genomic ∆CT H1-H2)] for SNP1 and 2^(-1.043*[(cDNA ∆CT H1-H2) – (Mean genomic ∆CT H1-H2)] for
SNP9ii.  For midbrain samples, the mean of the genomic ∆CT H1-H2 values for the eight iPS clones was used. 
Specific H1:H2 ratios for inclusion of exon 3 and exon 10 in MAPT transcripts were determined by dividing by
the respective H1:H2 ratio for total MAPT transcripts.
TaqMan Gene Expression Assays
Gene/Assay Description Assay ID
MAPT exon3+ transcripts (exon3-4) Hs00902315_m1 FAM/MGB/NFQ
MAPT exon 10+ transcripts (exon9-10) Hs00902312_m1 FAM/MGB/NFQ
MAPT all transcripts (exon12-13) Hs00902194_m1 FAM/MGB/NFQ
GAPDH Hs02758991_g1 VIC/MGB/NFQ
HPRT1 Hs02800695_m1 VIC/MGB/NFQ
ACTB Hs01060665_g1 VIC/MGB/NFQ
Primers and probes for allele-specific qRT-PCR TaqMan expression assays.
Primer/Probe Name Primer/Probe Sequence (5’-3’) Primer/Probe Purpose
MAPT exon 0 F CCTCGCCTCTGTCGACTATC MAPT all transcripts allele-specific
(exon 0-1)MAPT exon 1 R TACGTCCCAGCGTGATCTTC
MAPT exon 0 F CCTCGCCTCTGTCGACTATC MAPT exon 3+ transcripts allele-
specific (exon 0-3)MAPT exon 3 R GTCACATCTTCCGCTGTTGG
MAPT intron 0 F CCCCAACACTCCTCAGAACT MAPT allele-specific exon 1
genomicMAPT exon 1 R TACGTCCCAGCGTGATCTTC
MAPT exon 9 F AAGAGCCGCCTGCAGACA MAPT exon 10+ transcripts allele-
specific (exon 9-10)MAPT exon 10 R GGACGTTGCTAAGATCCAGCTT
MAPT exon 9 F AAGAGCCGCCTGCAGACA MAPT allele-specific exon 9
genomicMAPT intron 9 R ACCTCCATGCACAGTCCCA
SNP1 H1 Probe
(FAM/MGB/NFQ)
CTGGTTCAAAGTTC
SNP1 H2 Probe
(VIC/MGB/NFQ)
TGGTTCAAAGCTCAC
SNP9ii H1 Probe
(FAM/MGB/NFQ)
TTGGACTTGACATTCT
SNP9ii H2 Probe
(VIC/MGB/NFQ)
CTTGGACTTGACGTTCT
Western blotting
Cell pellets were sonicated in RIPA buffer (50 mM tris-HCl, pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100, 1%
(w/v) sodium deoxycholate, 0.1% (w/v) SDS) for standard Western blotting, or in TBS (20 mM tris-HCl, pH
7.4, 140 mM NaCl) when protein dephosphorylation would subsequently be performed; cOmplete mini protease
inhibitors (Roche) were added to both buffers. After 30 minutes incubation on ice, the soluble fraction was
isolated by micro-centrifugation (1200 x g, 20 min, 4 ºC). Protein concentrations were determined by BCA
assay (ThermoScientific) with a BSA calibration curve.
For protein dephosphorylation to reveal tau isoforms, 15-20 µg protein samples were incubated with lambda
phosphatase (NEB) (20 units/µl, 60 min, 30ºC) followed by denaturation in Laemmli sample buffer (Laemmli,
1970) (95 ºC, 10 min). Non-dephosphorylated blots had 5 µg protein loading. Protein separation was achieved
using 10% (dephosphorylated protein blots) or 4-15% (other blots) Criterion TGX polyacrylamide gels (Bio-
Rad) in a tris-glycine running buffer, with transfer to a PVDF membrane using the TransBlot-Turbo Transfer
System (Bio-Rad).
Blots were blocked with 5% milk (Sigma) in TBS with 0.1% (v/v) Tween 20 (TBST), incubated with primary
antibody in 1% milk-TBST (overnight, 4ºC), washed three times with TBST, probed with horseradish
peroxidase (HRP)-conjugated secondary antibody in 1% milk-TBST for 1 hour at room temperature, and
washed four times in TBST. Immobilon Western Chemiluminescent HRP Substrate (Millipore) was added and
chemiluminescence detected using the ChemiDoc Touch System (Bio-Rad). Bound proteins were removed
using Restore Western Blot Stripping Buffer (ThermoScientific, 15 min) and immunodetection was repeated
using additional antibodies. Primary antibodies used in this study: β3-tubulin (TUJ1) (1:1000, Covance, MMS-
435P), tyrosine hydroxylase (1:2000, Millipore, ab152), HRP-conjugated β-actin (1:20,000, abcam, ab49900), 
tau-1 clone PC1C6 (1:1000, Millipore, MAB3420), 4R tau repeat isoform RD4 (1:250, Millipore, 05-804), 2N
tau clone 71C11 (1:1000, Covance, Sig-39408), tau-5 (1:5000, NeoMarkers, MS-247-P). Secondary antibodies
used in this study: HRP-conjugated goat anti-mouse (1:5000, Bio-Rad, 170-6516), HRP-conjugated goat anti-
rabbit (1:5000, Bio-Rad, 170-6515).
Immunocytochemistry
Cultures grown on glass coverslips were washed with PBS, fixed with 4% (w/v) paraformaldehyde in PBS for
10-15 min and washed three times with PBS. Cell permeabilisation and protein blocking were performed with
10% goat serum in PBS 0.1% Triton X-100 (PBST, 2 hours) prior to incubation with primary antibodies in
PBST with 1% goat serum (4 ºC overnight). Coverslips were washed three times with PBST and incubated with
Alexa Fluor-labelled secondary antibodies for 1 hour to enable visualisation. Coverslips were washed with PBS
and incubated with 1 µg/ml DAPI (Sigma) in PBS for 5 min then washed again with PBS. Coverslips were
mounted on glass slides with FluorSave (Calbiochem) and cells imaged using an EVOS FL Auto Imaging
System (Life Technologies). Antibodies used in this study: TUJ1 (1:500, Covance, MMS-435P), tyrosine
hydroxylase (1:250, Millipore, ab152), Alexa-488 goat anti-mouse (1:500, Invitrogen, A11001), Alexa-594 goat
anti-rabbit (1:500, Invitrogen, A11012).
RNA extraction and cDNA synthesis
Midbrain samples were from healthy control subjects without any neurological symptoms obtained from the UK
MRC Control collection run by Oxford Brain Bank, University of Oxford. Samples were assessed by a
neuropathologist and any found to have protein deposition or morphological abnormalities except minor, age-
related Alzheimer’s changes were excluded from the analysis. Full ethical approval (REC15/SC/0639) and
written informed consent to brain and spinal cord donation were obtained from the relatives of all potential
tissue donors dying in the Oxford University Hospital Foundation Trust Hospitals.
Samples of frozen post-mortem human midbrain were obtained for MAPT H1/H2 individuals. Samples were
composed of several cryostat-generated horizontal sections that all included the substantia nigra. Before RNA
extraction, samples were homogenised in RNeasy Buffer RLT with 1% 2-mercaptoethanol using a TissueRuptor
(QIAGEN).
RNA was extracted from culture cell pellets or midbrain homogenate using RNeasy Micro/Mini kits (QIAGEN)
according to manufacturer’s instructions. RNA concentration was determined by Nanodrop (ThermoScientific).
RNA integrity number was determined for midbrain samples using a Eukaryote Total RNA Pico Assay on a
2100 Bioanalyzer System (Agilent Technologies) (n=9; mean = 6.6; median = 6.8, IQR = 1.6). First-strand
cDNA synthesis was performed using SuperScript VILO MasterMix (Invitrogen) according to manufacturer’s
instructions with a two-hour synthesis step.
Quantitative real-time polymerase chain reaction (qRT-PCR)
All qRT-PCR assays were run as 20 µl reactions on a StepOnePlus System using either TaqMan Gene
Expression Master Mix or Fast SYBR Green Master Mix (Applied Biosystems) with 200 nM of each primer. 5
ng or 10 ng cDNA was included in each reaction. TaqMan Gene Expression Assays were used to determine
expression of specific MAPT transcripts and multiplexed with VIC-labelled assays for housekeeping genes
(Applied Biosystems, Table S3). A common threshold value of 0.1 was set for all assays (except allele-specific
assays) to enable comparison. Expression of total MAPT, RBM4 and PTBP1 were determined as 2^–(Assay CT –
housekeeper geometric mean). MAPT isoform-specific assays were normalised to Total MAPT instead of
housekeeper assays, with exon % inclusion determined by the formula [2^–(MAPT isoform assay CT – Total
MAPT CT)]*100.
RNA electrophoretic mobility shift assay
SK-N-F1 cells were grown in 15 cm dishes for 48 hours and harvested by gentle scraping. The cytoplasmic
fraction was first extracted using cold lysis buffer: 10 mM HEPES (Sigma), 10 mM KCl (Ambion), 0.1 mM
EDTA (Ambion), 0.1 mM EGTA (Sigma), Halt protease and phosphatase inhibitor cocktails (Thermo
Scientific) and 0.67 % IGEPAL CA-630 (Sigma). The nuclear pellet was washed and lysed using cold nuclear
lysis buffer (20 mM HEPES, 400 mM KCl, 1 mM EDTA, 1mM EGTA and Halt protease and phosphatase
inhibitor cocktails.
RNA electrophoretic mobility shift assay (EMSA) was carried out using RNA oligonucleotides biotinylated at
the 3’ end, SK-N-F1 nuclear lysates and the LightShift Chemiluminescent RNA EMSA Kit (Pierce) according
the manufacturer’s protocol. RNA oligonucleotides containing intron 10 WT sequence: H1 (5’
TGCATAGAATAAATCCTTCTTGGGCTCTCAGGA 3’) and intron 10 ∆CTT sequence (5’ TGC ATA GAA 
TAA ATC CTT GGG CTC TCA GGA 3’). RNA probes contain the same sequence with a 15 atom
tetraethylene glycol linker biotin at the 3’ end of the oligonucleotide (Integrated DNA Technologies).
RNA-Protein pull-down
RNA pull-down of RNA binding proteins was performed using the Magnetic RNA Protein Pull-Down kit
(Pierce) according to the manufacturer’s instructions. 50pmol of biotinylated RNA oligonucleotides were
allowed to bind streptavidin magnetic beads and incubated with 40µg of SKNF1 nuclear enriched lysate for 1
hour at 4ºC. Unbound proteins were washed off and RNA-protein complexes were dissociated from the
magnetic beads by boiling in 5X Laemmli buffer for 10 min. The isolated RNA-protein complexes were loaded
onto a 10% Tris-glycine SDS-PAGE for western blotting. Blots were probed with anti-PTBP1 (1:1000, Abcam,
ab30317) and anti-RBM4 (1:500, Abcam, ab130624) antibodies
Generation of lentiviral constructs and production of lentiviral particles
shRNA sequences were identified to target MAPT exon 10 (corresponding to 4R tau), MAPT exons 12-13
(constitutive exons for targeting total MAPT) and no known RefSeq transcript (non-targeting shRNA).
Incorporation of shRNA sequences into lentiviral plasmids was performed using a modification of the PCR-
based protocol of Harper and Davidson (2005), using Gibson Assembly to perform all construction steps in one
(Fig. S3). The following DNA molecules were joined using Gibson Assembly Master Mix (NEB):
pRRL.sin.wpre fragment of SpeI-HF/SalI-HF double digest (NEB) of
pRRL.sin.U6.shRNA.cPPT.CMV.EGFP.wpre (kind gift from Dr Óscar Cordero Llana); PCR of U6 promoter
from the same construct, adding a specific shRNA sequence with the reverse primer; PCR of RRE.cPPT.pEF1α 
from CSii-EF-MCS (a gift from Dr H. Miyoshi, RIKEN BioResource Center DNA Bank); PCR of EBFP2 from
pBAD-EBFP2 (a gift from Robert Campbell, Addgene #14891)(Ai et al., 2007). All PCRs were performed
using KAPA HiFi HotStart ReadyMix (KAPA Biosystems); see Table S5 for primer sequences. All DNA
molecules were separated by agarose gel electrophoresis (2% for shRNA PCRs and 1% for all others), purified
by QIAquickGel Extraction Kit (QIAGEN) and quantified by Nanodrop before Gibson Assembly. Assembly
products were used to transform One Shot TOP10 Chemically Competent E. coli (Invitrogen) for growth and
selection, then One Shot Stbl3 Chemically Competent E. coli (Invitrogen) following verification and
sequencing.
For third generation production of lentiviral particles, the following plasmids were prepared by PureLink HiPure
Plasmid Maxiprep kit (Invitrogen) and transfected into HEK293T cells in 15 cm dishes: 10 µg shRNA/EBFP2
lentiviral vector; 10 µg pMDLg/pRRE (a gift from Didier Trono, Addgene #12251)(Dull et al., 1998); 2 µg
pRSV-Rev (a gift from Didier Trono, Addgene #12253); 3.4 µg pMD2.g (a gift from Didier Trono, Addgene
#12259) encoding vesicular stomatitis virus glycoprotein (VSV-G) for lentiviral pseudotyping.
HEK293T cells were transfected by calcium phosphate transfection, whereby DNA was incubated with 125 mM
CaCl2, 25 mM HEPES, 140 mM NaCl, 0.75 mM Na2HPO4 (Sigma) for 30 min before adding to HEK293T
cultures. On day two the culture medium was replaced, containing 10 mM sodium butyrate (Sigma), then
collected eight hours later as the first harvest. Following replacement, a second harvest of medium was
performed at the end of day three and pooled with the first harvest. Viral medium was centrifuged to remove
debris (1,000 x g, 5 min), 0.45 µm filtered, then centrifuged overnight to pellet viral particles (6,000 x g, 4ºC).
On day four the pellet was re-suspended in ice-cold PBS, ultra-centrifuged (20,000 x g, 90 min, 4ºC) and finally
re-suspended in 20 mM Tris base, 100 mM NaCl, 10 g/l sucrose, 10 g/l D-mannitol (Sigma); brief centrifugation
(1000 x g, 5 min, 4ºC) removed persistent debris before aliquoting for -80ºC storage.
Viral titres were determined by transduction of HEK293T cells with serial dilutions, followed by flow
cytometry determination of the percentage of EBFP2-positive cells 72 hours post-transduction.
Primers for construction of lentiviral shRNA plasmids by Gibson Assembly.
Primer Name Primer Sequence (5’-3’) with shRNA sequence shown in bold Primer Position
LenGib_1F TTCGCCCTTACGCTCTAGAAC Before U6
LenGib_x10R TGTCCCTCCTCGAGAAAAAAGGTGCAGATAATTAATAAGTTCGC
TTATTAATTATCTGCACCTTCGCAAACAAGGCTTTTCTCCAAG
To add shRNA
sequence against exon
10+ MAPT
LenGib_TotR TGTCCCTCCTCGAGAAAAAACCAGGTGGAAGTAAAATCTGATTC
GTCAGATTTTACTTCCACCTGGCGCAAACAAGGCTTTTCTCCAA
G
To add shRNA
sequence against total
MAPT
LenGib_Scr TGTCCCTCCTCGAGAAAAAAGAAGGCTCGTCGCACTAATTTCGA
TTAGTGCGACGAGCCTTCTTCGCAAACAAGGCTTTTCTCCAAG
To add scrambled
shRNA sequence
LenGib_2F TTTTTTCTCGAGGAGGGACAATTGGAGAAGTG Before RRE
LenGib_2R CTGCAGAATTCTCGAGACCG After pEF1α
LenGib_3F CGGTCTCGAGAATTCTGCAGGCCACCATGGTGAGCAAGGGCGAGG Start of EBFP2
LenGib_3R TGTAATCCAGAGGTTGATTGTCGACTTACTTGTACAGCTCGTCCAT
G
End of EBFP2
Mitochondrial axonal transport imaging
Cultures of iPS-derived dopaminergic neuronal cultures were transduced with lentiviral particles encoding
shRNAs on DIV20 following re-plating onto Geltrex-coated coverslips. Cultures were imaged on a Nikon
Eclipse TE-2000-U fluorescent microscope with heated chamber at 37ºC and delivery of 5% CO2/Air for up to
one hour with a 60X immersion objective (Nikon Plan APO VC, 60x/1.40 oil, 0.17, DIC, N2).
Image analysis
Kymograph time-space plots were generated from blinded videos in Fiji software (National Institutes of Health)
using the Multiple Kymograph plugin and the tsp050706 macro according to its protocol
(http://www.embl.de/eamnet/html/body_kymograph.html). For transduced coverslips, only EBFP2-positive
axons were chosen for analysis. Within the multiple kymograph, a segmented line was drawn along the path of
each mitochondrion and velocities were determined using the ‘read velocities from tsp’ macro. Due to the
complex network that develops in extended culture, the position of the cell body was not identified so
directionality could not be determined. Mitochondria were classed as motile if they moved more than 2 µm
during the imaging period, corresponding to the approximate length of a mitochondrion (Vossel et al., 2015).
Pauses were determined as individual parts of the path where a mitochondrion moved 0-1 pixels and/or had a
velocity <0.12 pixels/s (<0.0139 µm/s) corresponding to the minimum velocity needed to reach the overall
threshold of motility in the 150 s imaging window. Data are presented as average velocity (µm/s) for the
measured period and also the same average velocity calculation but with pause periods removed.
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